3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
13
Carcinoma, Renal Cell
6
Tuberous Sclerosis
5
Neoplasm Metastasis
5
Hodgkin Disease
5
Glioblastoma
5
Colorectal Neoplasms
5
Central Nervous System Neoplasms
5
Waldenstrom Macroglobulinemia
4
Stomach Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Pancreatic Neoplasms
4
Lymphoma, Mantle-Cell
4
Head and Neck Neoplasms
4
Gliosarcoma
4
Triple Negative Breast Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sezary Syndrome
3
Recurrence
3
Prostatic Neoplasms
3
Neoplasms
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Kidney Neoplasms
3
Interventions
pembrolizumab
3
Docetaxel
3
Cisplatin
3
Erlotinib Hydrochloride
2
Cetuximab
2
Carboplatin
2
spartalizumab
1
ixabepilone
1
entrectinib
1
Vorinostat
1
Tablets
1
Radiotherapy
1
Radiosurgery
1
RC48 antibody
1
Paclitaxel
1
Nivolumab
1
NVP-BKM120
1
Ipilimumab
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FPP(RGD)2
1
Everolimus
1
Epirubicin
1
Combined Modality Therapy
1
Chemoprevention
1
Capecitabine
1
CTLA-4 Antigen
1
Bevacizumab
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Salivary Gland Neoplasms
×
Everolimus
×
Clear all
NCT01313390
2011-12-12
DORA
University College, London
Phase 1/2
Terminated
4 enrolled